FIELD: medicine.
SUBSTANCE: invention discloses use of nanoparticles containing a matrix of at least one protein containing at least one anti-tumour active substance for preparing a medicinal agent for treating tumours whose resistance to chematherapeutic agents is associated with hyperexpression of P-glycoprotein, wherein the protein matrix includes at least one anti-tumour active substance which is not covalently bonded to said proteins.
EFFECT: doxorubicin nanoparticles in the disclosed medicinal agent and doxorubicin solution had comparable effect on non-resistant neuroblastoma cells; when resistance arose during therapy with cytostatic doxorubicin nanoparticles, the solution and liposomal preparation of doxorubicin were more effective in the disclosed agent.
4 cl, 2 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TUMOUR PREPARATION | 2011 |
|
RU2451509C1 |
| CONJUGATE OF ANTITUMOUR DRUGS WITH RECOMBINANT ALPHA-FETOPROTEIN AND ITS FUNCTIONAL FRAGMENTS AND METHOD OF THEIR PRODUCING | 2016 |
|
RU2630974C1 |
| MAGNETIC NANOPARTICLE FOR TREATING AND/OR PREVENTING CANCER, BASED INFUSION SOLUTION AND PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2490027C9 |
| FILLED WITH ACTIVE SUBSTANCE NANOPARTICLES BASED ON HYDROPHILIC PROTEINS | 2007 |
|
RU2424819C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING DOXORUBICIN AS PART OF PHOSPHOLIPID NANOPARTICLES USING SELECTIVE DNA APTAMER MOLECULES FOR TARGETED TRANSPORT TO TUMOR CELLS | 2021 |
|
RU2794798C1 |
| HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
| CARRIER SYSTEM IN FORM OF NANOPARTICLES BASED ON PROTEIN FOR CELL-SPECIFIC ENRICHMENT OF ACTIVE MEDICAL AGENTS | 2005 |
|
RU2388463C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
| MEDICINAL PRODUCT FOR TREATMENT OF BREAST CANCER | 2017 |
|
RU2657545C1 |
| POLYPEPTIDE DISPLAYING ANALOG OF RECEPTOR-BINDING EPIDERMAL GROWTH FACTOR FRAGMENT FROM 21 TO 31 AMINO ACIDS, ITS CONJUGATE WITH DOXORUBICIN AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2196604C1 |
